Opportunities in interventional oncology by henry wanga
1. Opportunities in interventional oncology
Dr. Henry Wanga
Consultant Interventional Radiologist
Zenith Medical Centre
General Accident Insurance House
Ralph Bunche Road, Upper Hill Nairobi
2. KESHO
Kenya Society of Hematology and Oncology Third
Annual Scientific Conference
Panafric Hotel, Nairobi Kenya
28th November 2014
3. Angiography, Biopsy and Drainage
Interventional Radiology(IR) is a clinical subspecialty with a rich history of
innovations
We approach our work through clinical problem solving with our referring
specialists
Many IR practices have shifted from peripheral vascular interventions to
interventional oncology
Multimodal imaging methods have superseded the traditional arteriography
Embolic agents can be permanent, temporary, or combined with an agent
such as chemotherapy
Pelvic malignancies may cause lower extremity deep vein thrombosis.
Treatment is by placing permanent or temporary inferior vena cava filters
Complications in IR practice are uncommon
4. Oncologic applications
VASULAR
A. diagnostic information(e.g. vascular invasion, biopsy)
Diagnosis and treatment of associated conditions,(DVT,
central venous access, hemorrhage)
Local delivery of chemotherapy
Embolotherapy
Brachytherapy delivery
2. NON-VASCULAR
Diagnostic information(PTHC, biopsy)
Treatment of associated conditions (e.g. GI/GU/ biliary
obstruction)
Local tumor ablation(RF/ thermal, ethanol,acetic
acid,cisplatin -epigel)
5. Continued Oncologic applications
Brachytherapy delivery
3. Disease control vs. palliation
4. Connections with Basic Science(small animal, cellular
culture, etc) and Clinical Research(clinical trials)
7. Agents used in embolization treatment
of malignancies
Gelfoam sponge temporary –haemostasis
Poly vinyl alcohol particles (PVA) - permanent occlusion.
Comes in sizes 100, 200, 300, 500,700,or 1000 microns
Drug eluting beads (DEB)
Coils
8. Chemo infusion Agents
Cisplatin
Doxorubicin
Mitomycin c
Paclitaxel
And many others
9. Hepatocellular carcinoma: Solitary
tumor <3 cm
Treatment/Procedure Rating Comments
Systemic chemotherapy 3
Resection 8
Transplantation 9
Chemical ablation 6
Thermal ablation 8
Tran arterial embolization (TAE) 5
Tran arterial chemoembolization (TACE) 5
Selective internal radiation therapy (SIRT) 5
Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate
10. Hepatocellular carcinoma: Solitary
tumor 5 cm
Treatment/Procedure Rating Comments
Systemic chemotherapy 3
Resection 8
Transplantation 9
The tumor is too large for chemical ablation. May
Chemical ablation 3 use it instead of or in addition to thermal ablation
depending on tumor location.
Thermal ablation 5
Tran arterial embolization (TAE) 6
Tran arterial chemoembolization (TACE) 7
Selective internal radiation therapy (SIRT) 7
Especially applicable in portal vein thrombosis or
extensive bilobar disease.
Transarterial chemoembolization (TACE)
7
combined with thermal ablation
Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate
11. Metastatic liver disease: Multifocal colorectal carcinoma (liver
dominant or isolated), 5 cm
tumors.
Treatment/Procedure Rating Comments
Systemic chemotherapy 9
Resection 7
Transplantation 1
Chemical ablation 1
Thermal ablation 2
Hepatic arterial chemotherapy infusion 5
Transarterial embolization (TAE) 5
Transarterial chemoembolization (TACE) 5
Selective internal radiation therapy (SIRT) 5
Transarterial chemoembolization (TACE)
5
Depends on tumor burden.
combined with thermal ablation
Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate
15. IGS for Interventional Oncology
Innova* Image Guided Systems (IGS) for Interventional
Oncology provide excellent image quality with
exceptional dose efficiency. Get excellent organ coverage
for tumor embolization, ablation techniques, and 3D
guidance. Our flagship Innova IGS 540 with the Innova
CT option enhances soft tissue visualization for imaging
of high- and low-density tissues.
25. Discussion
Hepatocellulacr carcinoma is the most common primary
malignancy of the liver
Predisposed in patients with chronic liver diseases such as
cirrhosis, hemochromatosis, alcoholism and glycogen
storage disease
Hepatitis Chas been attributed to lead to increase HCC in
the United States. Age at presentation is in the sixth and
seventh decades
In Kenya the incidence is in the fourth and fifth decades
26. Major patterns of growth of HCC
Solitary mass
Multifocal masses
Diffusely infiltrating mass
27. Hepatic metastasis
This is the most common malignancy of the liver arising
from the colon, stomach, pancreas, breast, and lung
neoplasm
In children, metastases are commonly from neuroblastoma
and Wilm’s tumor
Prognosis depends on the primary tumor site.
31. Acknowledgements
Aga Khan University hospital, Karachi, Pakistan
Lifestyle, hospital, Pretoria
The Nairobi Hospital
Many colleagues; Dr. Abwao, Dr. Njuguna, Dr.
Ndagwatha, Dr. Githaiga, Dr. Otele, Dr. Nyongesa, Dr.
Ochieng( now studying in South Africa)
Radiology colleagues especially the late Dr. Sara Goretti
Tata
Colleagues at Mulago Hospital, Makerere University,
Kampala Uganda
Indeed all of YOU